Lilly to roll out orforglipron
Eli Lilly said it plans to launch its oral GLP‑1 drug orforglipron — sold as Foundayo in some markets — in about 40 countries including India. The announcement follows regulatory clearances abroad and signals broader global availability for another oral weight‑loss option (news9live.com). Reporting also noted the wider industry trend toward oral GLP‑1 options becoming commercially available (news9live.com).
Eli Lilly is preparing to sell its daily obesity pill orforglipron in about 40 countries, including India, after winning United States approval on April 1. (investor.lilly.com, news9live.com) In the United States, Lilly markets orforglipron as Foundayo for adults with obesity, or adults who are overweight and have at least one weight-related medical problem. The Food and Drug Administration said the tablet is taken once a day with diet and exercise and does not need to be taken on an empty stomach. (fda.gov, investor.lilly.com) The India plan is still subject to local approval. Winselow Tucker, Lilly India’s president and general manager, said India is part of the company’s global rollout, but Lilly did not give a filing date or launch date for the country. (moneycontrol.com, news9live.com) These drugs mimic a gut hormone called glucagon-like peptide-1, which helps people feel fuller and can lower blood sugar. Lilly says orforglipron is a small-molecule pill, not a peptide injection, which lets patients take it without food or water restrictions. (investor.lilly.com, fda.gov) Lilly is pushing the pill as a simpler alternative to weekly shots such as its own Mounjaro, which already sells in India. Moneycontrol reported that Mounjaro was the first glucagon-like peptide-1 medicine to enter India’s market for diabetes and weight loss. (moneycontrol.com) The company’s obesity study, called ATTAIN-1, included India among its trial countries. Lilly said adults who stayed on the highest dose lost an average of 27.3 pounds, or 12.4 percent of body weight, compared with 2.2 pounds on placebo. (investor.lilly.com, moneycontrol.com) In a separate late-stage diabetes trial released in April 2025, Lilly said orforglipron lowered hemoglobin A1C by 1.3 to 1.6 percentage points at 40 weeks and reduced weight by 16.0 pounds at the highest dose. Lilly said that program was the first successful Phase 3 trial for an oral small-molecule glucagon-like peptide-1 drug. (investor.lilly.com) The United States approval moved unusually fast. The Food and Drug Administration said it cleared Foundayo 50 days after filing under its Commissioner’s National Priority Voucher pilot program, 294 days ahead of the original January 20, 2027 target date. (fda.gov) Lilly told investors in 2025 that it expected to launch orforglipron worldwide without supply constraints, a point that matters in a market where injectable glucagon-like peptide-1 drugs have faced shortages. The next test is whether regulators outside the United States, including India’s, move quickly enough for Lilly to turn that manufacturing push into sales. (investor.lilly.com, biospace.com)
